EHC: Recognizing Von Willebrand Factor as a Critical Medicine in Bleeding Care
The European Haemophilia Consortium (EHC) recently shared a post on X:
”Von Willebrand Disease affects 1:1000 individuals and, if not recognised, may cause severe bleeding symptoms after trauma or surgery that can be life-threatening. It’s time for health systems to recognise Von Willebrand Factor as a Critical Medicine. European Medicines Agency”
Von Willebrand Disease (VWD), the most common inherited bleeding disorder, affects approximately 1 in 1,000 individuals.
When unrecognized or untreated, it can lead to serious, even life-threatening bleeding, particularly after trauma or surgical procedures.
Despite its prevalence and potential severity, VWD remains underdiagnosed and undertreated in many health systems.
There is an urgent need to designate Von Willebrand Factor (VWF) as a Critical Medicine to ensure timely diagnosis, treatment access, and improved outcomes for patients.
Recognizing VWF’s essential role in bleeding management is a key step toward better care for individuals living with VWD worldwide.
Hemostasis Today, your daily update on the waves in bleeding disorders community.
-
Aug 26, 2025, 10:02Women’s Equality Day: HFA Recognizes Women with Bleeding Disorders
-
Aug 26, 2025, 09:59Rare Disease Advisor – RBC Rheology Alterations in Hemophilia with Arthropathy
-
Aug 26, 2025, 09:57HFA Supports Future Planning for People with Bleeding Disorders
-
Aug 26, 2025, 09:56Phillip Taboada: TXA Shows No Added Benefit in Aquablation
-
Aug 26, 2025, 09:50A Global Collaboration: PERT Consortium Expands Reach in PE Care
-
Aug 26, 2025, 09:54TSUBASA Study: Emicizumab Improves Daily Life and Motivation in Hemophilia A Patients
-
Aug 26, 2025, 09:38Advancing CAT Care: New Insights on Extended Anticoagulation from Gerotziafas and Tafur
-
Aug 26, 2025, 09:35Alexander Mazein: Innovative Insights into Cytokine Release Syndrome via a Novel Explorable Model for Biotherapeutics and Cellular Therapies
-
Aug 25, 2025, 10:40Maria Filomena Ruberto on The Hypercoagulable State
-
Aug 25, 2025, 09:19Parham Dastjerdi – Clonal Hematopoiesis and VTE Risk
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Aug 26, 2025, 09:42David McIntosh Highlights Global Blood Shortages and Fresh vs Stored RBCs
-
Aug 23, 2025, 07:48Protecting Heart and Brain Health: Stroke Prevention in Women with Bleeding Disorders: NBDF
-
Aug 21, 2025, 15:08Global Variations in Blood Collection: What Explains the Differences?
-
Aug 20, 2025, 13:33Askat's Life with Hemophilia A after Access to Prophylactic Treatment Through the WFH Humanitarian Aid Program
-
Aug 19, 2025, 17:22Louise Bannon Encourages You to Support World Thrombosis Day!